Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
04/2003
04/09/2003EP0669837B1 Restrained multifunctional reagent for surface modification
04/09/2003EP0620012B1 Double contrast x-ray contrast medium for examining large and small intestines
04/09/2003CN1409758A Stabilizing diluent for polypeptides and antigens
04/09/2003CN1409724A 雌二醇轭合物和其用途 Estradiol conjugates and uses thereof
04/09/2003CN1409720A Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
04/09/2003CN1409682A Injection-moulded water soluble container
04/09/2003CN1409641A DNA- vaccine based on constructs drived from genomes of human and animal pathogens
04/09/2003CN1409640A Polypeptide composition with improved stability
04/09/2003CN1409636A Use of honey in medical dressings
04/09/2003CN1409631A New formulation
04/09/2003CN1409630A Sustainable-release formulations for treating CNS-mediated disorders
04/09/2003CN1409628A Adhesive preparations
04/09/2003CN1409627A Novel apparatus and process for preparing crystalline particles
04/09/2003CN1409605A Method for increasing pet activity
04/09/2003CN1408435A Method for medicinal matter for nose
04/09/2003CN1408342A Physical stable spraying gel composition
04/09/2003CN1408339A Skin external preparation
04/09/2003CN1408336A Complex room container preparation
04/09/2003CN1408226A Biological film sterilizing and disinfecting agent
04/09/2003CN1104911C Improvements in or relating to contrast agents
04/09/2003CN1104901C Medicinal preparation containing lipophilicity inert gas
04/09/2003CN1104899C Injectable quinolone formulations
04/09/2003CN1104891C Controlled release preparation
04/09/2003CN1104849C Stabilisation of flavourants
04/08/2003US6546284 Fluid retention assembly for an iontophoretic delivery device and associated method for preparing the same
04/08/2003US6545169 Anticancer, antiprotozoa agents
04/08/2003US6545162 Solid phase biosynthesis of viricide antibiotic
04/08/2003US6545131 Tissue specific prodrug
04/08/2003US6545126 Chimeric toxins
04/08/2003US6545097 Biocompatible block copolymer comprising one or more elastomeric blocks and one or more thermoplastic blocks connected by a seed polymer
04/08/2003US6545052 Contacting skin with skin treatment composition having concentration of 1-(3-methoxybenzyl)-3-substituted thiourea compound effective for inhibiting free radical generation
04/08/2003US6545048 Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
04/08/2003US6545036 Potassium channel blockers; neuroprotectants, glaucoma, n-benzoyl indole compounds with 3-acylureamethyl group
04/08/2003US6544991 Compositions and methods for treating bacterial infections
04/08/2003US6544966 Agents promoting laminin production in skin cells
04/08/2003US6544954 Demonstrate high stability after sterilization by autoclaving and storage at 80 degrees C. for at least two weeks
04/08/2003US6544646 Zero order release and temperature-controlled microcapsules and process for the preparation thereof
04/08/2003US6544561 Neutral to mildly alkaline; preventing and/or treating certain inflammatory diseases and/or degenerative diseases and/or certain viral diseases in a mammal
04/08/2003US6544559 Such as 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8,9 -tetrahydro-2-methyl-4H-pyrido (1,2-a)pyrimidin-4-one for sustained-release via biodegradation; for treatment of mental illness
04/08/2003US6544558 Granulates compacted together into a tablet form together with an extra-granular lubricant; especially amoxycillin plus clavulanic acid, and crosslinked polyvinylpyrrolidone or sodium starch glycolate intra-granular disintegrant
04/08/2003US6544556 Prevents gastrointestinal side effects
04/08/2003US6544554 Time-release agents
04/08/2003US6544552 Method of producing porous tablets with improved dissolution properties
04/08/2003US6544551 Solid pharmaceutical compositions containing hexedecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis
04/08/2003US6544548 Hydratable keratin solid which forms a hydrogel upon addition of water for use in nonwoven films, diapers, skin treatments, prosthetic devices, excipients, tissue engineering scaffolds; controlled drug delivery
04/08/2003US6544544 Compound which disrupts microtubule function and polymeric carrier, with proviso that polymeric carrier is not a capsule
04/08/2003US6544543 Depositing layer of polymer on luminal surface of target vessel; injecting microspheres containing vasoconstrictor into patient, wherein microspheres are adapted to attach to layer of polymer and release vasoconstrictor in situ
04/08/2003US6544530 Stable oil-in-glycerin emulsion
04/08/2003US6544510 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
04/08/2003US6544509 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
04/08/2003US6544508 Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799)
04/08/2003US6544502 Skin treatment with a water soluble antibiotic dissolved in an electrolyzed water
04/08/2003US6544497 Modulated release particles for aerosol delivery
04/08/2003CA2333701C .alpha.-hydroxy fatty acid derivatives and external compositions containing the same
04/08/2003CA2224983C Triazole antifungal agents
04/08/2003CA2191344C Synthetic peptide analogs of lung surfactant protein sp-c
04/08/2003CA2175471C Sucrose distearate lipid vesicles
04/08/2003CA2103829C Peg-interferon conjugates
04/08/2003CA2074322C A composition for the sustained and controlled release of medicamentous substances and a process for preparing the same
04/08/2003CA2071623C Cyclodextrin composition
04/04/2003WO2002030436A1 Method for producing phyllanthus extracts
04/04/2003WO2002030390A2 Method for producing powdery formulations
04/04/2003CA2424930A1 Method for producing phyllanthus extracts
04/03/2003WO2003027250A2 Monoclonal antibodies to the drug tilmicosin and a method for detecting the same
04/03/2003WO2003027169A1 Material consisting of at least a biodegradable polymer and cyclodextrins
04/03/2003WO2003027154A1 Polymers with structure-defined functions
04/03/2003WO2003027148A1 Disulfide-reduced neogalactosyl serum albumin and use of radiolabeled derivative thereof for liver imaging
04/03/2003WO2003027135A2 Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
04/03/2003WO2003026743A2 Opioid formulations having reduced potential for abuse
04/03/2003WO2003026701A1 Transporting of taxoid derivatives through the blood brain barrier
04/03/2003WO2003026699A1 Medicinal compositions promoting drug absorption
04/03/2003WO2003026697A2 Organoleptically acceptable intraorally disintegrating compositions
04/03/2003WO2003026689A1 Autologous growth factor cocktail composition, method of production and use
04/03/2003WO2003026687A1 Delivery system for biological component
04/03/2003WO2003026674A1 Coadministration of transport protein with conjugated cobalamin to deliver agents
04/03/2003WO2003026671A1 Method of treating middle ear infections
04/03/2003WO2003026656A1 New formulations and use thereof
04/03/2003WO2003026655A1 New formulations and use thereof
04/03/2003WO2003026654A1 Nicotine-containing film preparation
04/03/2003WO2003026642A1 Freeze-dried pharmaceutical preparation
04/03/2003WO2003026637A2 Dosage form for treatment of diabetes mellitus
04/03/2003WO2003026630A1 Dosage forms having an inner core and outer shell with different shapes
04/03/2003WO2003026629A2 Modified release dosage forms
04/03/2003WO2003026628A2 Composite dosage forms having an inlaid portion
04/03/2003WO2003026627A1 Composite dosage forms
04/03/2003WO2003026626A2 Modified release dosage forms
04/03/2003WO2003026625A1 Modified release dosage forms
04/03/2003WO2003026624A1 Modified release dosage forms
04/03/2003WO2003026623A1 Intraorally disintegrating valdecoxib compositions
04/03/2003WO2003026622A1 Lisinopril compositions having large-particle dcpd
04/03/2003WO2003026621A2 Method for making an oral pharmaceutical product with tell-tale agents, in particular of taste and resulting product
04/03/2003WO2003026620A1 Method for producing tablets from plant extracts
04/03/2003WO2003026617A2 (ester)-lysolecithins in liposomes
04/03/2003WO2003026616A1 Edible composition and dosage form comprising an edible shell
04/03/2003WO2003026615A2 Modified release dosage forms
04/03/2003WO2003026614A1 Dosage form containing a confectionery composition
04/03/2003WO2003026613A1 Fondant-based pharmaceutical composition
04/03/2003WO2003026612A2 Dosage forms having an inner core and outer shell
04/03/2003WO2003026611A2 Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
04/03/2003WO2003026610A2 Process for the preparation of fast dissolving dosage form
1 ... 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 ... 1712